Evotec
Dr. Oliver Steinebach has significant work experience in financial accounting and reporting. From 2023 onwards, they have held the position of Vice President Group Accounting Consolidation at Evotec. Prior to this, they worked as a Senior Group Consolidation Expert at the same company. From 2021 to 2023, Dr. Steinebach was a Team Leader for Financial Accounting & Reporting at Schindler Deutschland. Before that, they served as the Manager IFRS Group Accounting at Merck Gruppe from 2019 to 2021. Dr. Steinebach started their career in 2016 as a Research Associate with an academic degree at the University of Bremen, where they contributed until 2019.
Dr. Oliver Steinebach holds a Ph.D. degree in Accounting and Finance from the University of Bremen.
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.